Navigation Links
Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/10/2010

compared to Zyvox ® in a Phase 2 clinical study in complicated skin and skin structure infections (cSSSI).  In addition to PTK 0796, Paratek is also developing other tetracycline antibiotics to treat hospital and community infections based on its novel tetracycline chemistry expertise.

Based upon a growing body of clinical research and as part of its effort to exploit its novel tetracycline derivatives and their unique mechanism of action in selected inflammatory and neurodegenerative conditions, Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing nonantibacterial tetracycline derivatives with improved activity in serious inflammatory and neurodegenerative diseases.  In addition, Paratek is encouraged by early evidence of the ability of tetracycline derivatives to affect mRNA splicing, as in spinal muscular atrophy (SMA).  Outside of its tetracycline antibacterial program, Paratek has also identified small molecules that inhibit bacteria-specific transcription factors for Multiple Adaptational Response (MAR) genes which control bacterial virulence and resistance development.

Paratek has active collaborations with Novartis, Warner-Chilcott and FSMA to develop tetracycline-derived small molecule drugs for a range of uses, including bacterial infections, acne & rosacea and SMA.  Paratek is privately held and headquartered in Boston, Massachusetts, USA.  For more information about Paratek and its research and development initiatives, visit Paratek's website at http://www.paratekpharm.com.


'/>"/>
SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
3. Martek to Present at Upcoming UBS Conference
4. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
5. Kendle to Present at Robert W. Baird & Co. 2010 Health Care Conference
6. Weikang Bio-Technology to Present at Rodman and Renshaws Annual Global Investment Conference on September 14th 2010
7. Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference
8. Lexicon to Present at Morgan Stanley Global Healthcare Conference
9. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
11. The Female Health Company to Present at Rodman & Renshaws Annual Global Investment Conference on Wednesday, September 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 Ryan Carfley , Managing ... to sit down with Bryan Hamilton, the publisher of the ... discuss talent in the Research Triangle region of North Carolina. ... highlighted at the roundtable include the role of social ... of work/life balance and the unique role that Millennials play ...
(Date:10/27/2014)... -- The Italian company Roadrunnerfoot has ... its artificial "lower limb", after the German giant ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... judgement has arrived: Roadrunnerfoot, the small Italian company ... prostheses with composite materials, has won against global ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information says ... Ebola concern in the United States ... The healthcare market researcher said the FDA,s Emergency Use Authorization ... diagnostic tests for the detection of the Ebola virus ... useful.  Kalorama routinely assess the IVD industry and its ...
(Date:10/27/2014)... MA (PRWEB) October 27, 2014 ... profit. SoundConnect , an industry leading unified ... its partners and agents to deliver cloud-based audio ... accelerate growth opportunities. , With SoundConnect’s Q4 ... every twenty-five video and/or web conferencing licenses sold, ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3SoundConnect Unveils Q4 Partner Incentives 2
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... a biotechnology company developing peptide therapeutics for metabolic diseases, ... as Chief Executive Officer. Dr. Gottesdiener joins Rhythm from ... President and Late-Stage Therapeutic Group Leader, with responsibility for ... and previously as head of early-stage clinical development programs. ...
... -- an open-source, web-based platform for data-intensive biomedical ... a "cloud computing" resource. A team of researchers ... and molecular biology at Penn State University; Kateryna ... State; and James Taylor from Emory University, developed ...
Cached Biology Technology:Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Rhythm Names Keith M. Gottesdiener Chief Executive Officer 2Galaxy DNA-analysis software is now available 'in the cloud' 2Galaxy DNA-analysis software is now available 'in the cloud' 3
(Date:10/29/2014)... York City on September 19, 2014, leading geneticist and ... of Genome Sciences and Medicine at the University of ... of Tel Aviv University, was awarded the 2014 Lasker-Koshland ... to her honorary degree from TAU, Prof. King was ... Medicine, and for the past 18 years she has ...
(Date:10/29/2014)... Cambridge, MA and Hebei, China — BGI Tech and ... sequencing of the Jujube genome. Jujube is the most ... Jujube genome is particularly difficult to sequence due the ... is the first time that a genome in the ... been recently published in Nature Communications ...
(Date:10/28/2014)... One of the tragic realities of cancer is ... highly toxic and their effectiveness varies unpredictably from ... is poised to change this reality by rapidly ... on an individual,s cancer before chemotherapy begins. , ... headed by Assistant Professor Melissa Skala has developed ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3
... of the embryo in the uterus have found a ... vessels that sustain the embryo. Without this protein, which is ... embryo is unlikely to survive. This is the first ... estrogen spurs cell differentiation and blood-vessel growth in the uterus ...
... techniques are increasing hope of restoring fertility for women ... destruction of reproductive tissue. The same techniques can also ... protect against extinction of endangered animal species by maintaining ... can used to produce offspring at some point in ...
... percent of fish species in North American streams, rivers ... most detailed evaluation of the conservation status of freshwater ... 700 fishes now listed represent a staggering 92 percent ... previous 1989 study published by the American Fisheries Society. ...
Cached Biology News:Gap junction protein vital to successful pregnancy, researchers find 2Cryopreservation techniques bring hopes for women cancer victims and endangered species 2Silent streams? Escalating endangerment for North American freshwater fish 2Silent streams? Escalating endangerment for North American freshwater fish 3